Cosette Pharmac Patent-Cliff Exposure & CMS Drug Spending Portfolio

Cosette Pharmac (US): 10 reconciled FDA prescription therapies, $29.4M 2024 CMS Part D & Medicaid spend, and 31 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies10
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$29.4M
2024 Medicare Part D Spend$10.2M
2024 Medicaid Spend$19.1M
California HCAI SB 17 Filings31 WAC filings (max 282.7% 2-yr change)